Generated by AI
Eloxx Pharmaceuticals, Inc. Common Stock represents equity in Eloxx Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing novel small-molecule medicines that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations. The company’s current pipeline centers on exaluren, which is being studied for rare kidney diseases such as nonsense mutation Alport syndrome and autosomal dominant polycystic kidney disease, along with related ultra-rare genetic conditions. Eloxx also has a licensed program, ZKN-013, being advanced for rare dermatological diseases associated with nonsense mutations. Headquartered in Arlington, Massachusetts, Eloxx Pharmaceuticals operates in the biotechnology sector and serves a specialized niche in precision therapies for rare and ultra-rare disorders.
WebsiteP.O. Box 274
Arlington, MA, 02476
United States
The latest articles about ELOX.
Summary of Jun 17's posts. Generated by AI.
Summary of Jul 13's posts. Generated by AI.
Analysts initiated coverage: Neutral on RDW, Overweight on ELOX, Buys on SGHT and AU, and Market Perform on FFIN.
Summary of Apr 10's posts. Generated by AI.
Summary of Jun 17's posts. Generated by AI.
Investors talking about ELOX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.